Protein profiling startup Nomic Bio has secured $17 million in an oversubscribed series A financing led by Lux Capital. The funds will be used to expand the company’s servicing and manufacturing labs in Montreal and Boston, to broaden access to its proteomic platform by scaling profiling capacity to 100,000 samples per quarter starting in the second quarter of 2022 and by scaling its protein-detection method, called nELISA, to 500 on-boarded proteins.

Med-tech financings in 2021 have reached 673 transactions valued at $48.04 billion. This compares with 718 transactions valued at $59.7 billion in 2020, indicating a drop this year of about 6% in terms of volume and nearly 20% in terms of value. Nevertheless, 2021 is the second-best year of the last five.

Suki AI Inc. recorded $55 million in a series C fundraising round to support further development of its artificial intelligence (AI)-driven voice technology and digital clinical assistant for health care providers. The round was led by March Capital with participation by Philips Ventures. All previous investors in the company also returned, including Gaingels Group, Pankaj Patel (former chief development officer of Cisco), Andrew Deutsch (CEO of RIMA Radiology), and Russell Farscht (former managing director of The Carlyle Group).

PARIS – Wishbone SA closed a $3 million funding round, which should allow it to obtain the CE mark prior to launching its range of products in Europe based on bone regeneration technology for reconstructive dental surgery. “Thanks to this round, we are ramping scale and moving from R&D to the commercialization phase in Europe,” Daniel Bee, CEO of Wishbone, told BioWorld.

PERTH, Australia – Health care artificial intelligence (AI) company Harrison.ai has raised AU$129 million (US$97 million) in a series B round that will expand the company’s global footprint by commercializing its comprehensive clinical AI applications.

Medimaps Group SA has landed $20 million to expand its portfolio of bone health imaging software. The round was led by Swisscanto Invest, the asset management arm of the Zürcher Kantonalbank group, with participation from the Swiss Entrepreneurs Fund, Swisscom Ventures, and Verve Ventures. The company’s flagship product TBS (trabecular bone score) Insight is an artificial intelligence-powered medical software which provides information on bone quality from routine DXA and X-ray images.